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Pharmacomechanical thrombolysis for renal
salvage after filter migration and renal vein
thrombosis
Misaki Kiguchi, MD, Kerry-Ann McDonald, MD, Siddarth Govindarajan, BS, Michel S. Makaroun, MD,
and Rabih A. Chaer, MD, Pittsburgh, Pa
A 64-year-old woman underwent prophylactic inferior vena cava filter placement immediately after spinal surgery for
pulmonary embolus prophylaxis. One week after surgery, acute renal failure developed, and she required hemodialysis
secondary to filtermigrationwith iliocaval and renal vein thrombosis. Pharmacomechanical thrombolysis was performed,with
complete recovery of renal function and no evidence of recurrence on follow-up imaging. This report highlights an important
and rare complication of filter placement and the importance of prompt thrombus debulking to preserve end organ function
while reducing the risks of hemorrhagic complications. Pharmacomechanical thrombolysis allows prompt clearance of venous
outflow channels and is attractive in patients with end-organ compromise and high risk for bleeding. (J Vasc Surg 2011;53:
1391-3.)
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wMigration is a well-documented complication of infe-
rior vena cava (IVC) filters placement1 and can propagate
caval thrombus to involve the renal veins, resulting in acute
renal failure. Catheter-directed thrombolysis (CDT) has
become the preferred treatment for symptomatic caval
thrombosis.2 We describe the successful use of pharmaco-
mechanical thrombolysis (PMT) with adjunctive CDT to
promptly restore venous outflow after bilateral renal vein
and extensive caval thrombosis after IVC filter migration.
CASE REPORT
A 64-year-old woman with degenerative disk disease underwent
an L4-L5 epidural steroid injection in February 2009. Magnetic
resonance imaging 1 month later demonstrated L4-L5 osteomyelitis
and a vertebral body collection with spinal canal compromise. Under
general anesthesia without epidural, the patient underwent root de-
compression. A prophylactic G2 IVC filter (Bard Inc, Tempe, Ariz)
was placed on postoperative day 1 in the appropriate infrarenal posi-
tion in a 2.4-cm vena cava (Fig 1, A) because anticoagulation was
contraindicated. One week later, she underwent posterior lumbar
laminectomy with decompression of the L3-S1 nerve.
The patient was transferred to a rehabilitation facility 7 days
postoperatively. The IVC filter was not removed before discharge
due to ongoing immobility.
Two days after discharge, the patient was readmitted for
hypotension and tachycardia. She was oliguric, with gross hema-
turia and massive lower extremity swelling. Her serum creatinine
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doi:10.1016/j.jvs.2010.10.126evels had increased to 2.8 mg/dL from a baseline within normal
eference ranges. After a negative ventilation perfusion scan ruled
ut a pulmonary embolus, a noncontrast computed tomography
can demonstrated suprarenal filter migration with bilateral peri-
ephric stranding. No evident thrombosis was identified, due to
he lack of intravenous contrast use. Ultrasound imaging demon-
trated IVC and bilateral renal vein thrombosis, along with bilat-
ral iliofemoral and popliteal vein thrombosis. The patient was
ransferred to the vascular surgery service for further treatment.
From a prone bilateral popliteal approach, PMT of ilio-
emoropopliteal and intrafilter thrombus was performed using
he DVX AngioJet (Possis Medical, Minneapolis, Minn) and Trellis
Bacchus Vascular, Santa Clara, Calif) devices with the tissue plasmin-
gen activator Alteplase (Genentech, San Francisco, Calif) and the
ower pulse technique.3 The central balloon of the Trellis was simul-
aneously inflated above the migrated filter (Fig 1, B and C). The
ngioJet catheter was selectively activated within each renal vein (Fig
, A and B), followed by catheter aspiration of residual thrombus.
Although thrombus clearance from the popliteal, iliofemoral,
aval, and renal veins was achieved, persistent flow-limiting intra-
lter thrombus (Fig 2, C) required treatment with low-dose CDT
nd Alteplase. Alteplase was infused at 0.5 mg/h through a Cragg-
cNamara catheter (ev3, Plymouth, Minn) for 12 hours.
Repeat PMT for residual intrafilter thrombus was done using
he AngioJet device and achieved complete thrombus clearance
Fig 3, A). Filter retrieval attempts in the same setting were
nsuccessful due to filter tilt.
Hemodialysis through a catheter was acutely initiated. Intra-
enous heparin and oral anticoagulation were started. Three days
ater, the patient noted loss of bowel function and progressive
umbness of the right leg. A supratherapeutic international nor-
alized ratio of 5.0 was noted. A lumbar spine computed tomog-
aphy scan revealed an epidural hematoma, requiring evacuation.
The filter, tilted from initialmigration, was retrieved 11 days later
rom a dual internal jugular and femoral approach (Fig 3, B andC). A
lidewire and Omniflush catheter (AngioDynamics, Latham, NY)
ere introduced from the right femoral vein and looped across the
lter apex to straighten the tilt. An 8-mm angioplasty balloon was
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Systems, South Jordan, Utah) was successfully used to engage the
hook of the filter and collapse it into a sheath.
The patient underwent a nondiagnostic hypercoagulable
workup, and the venous thrombosis was attributed to surgical
immobility and concomitant filter migration. The patient was
restarted on warfarin and was discharged to a rehabilitation facility.
She had complete recovery of renal function after 1 month of
Fig 1. Initial ascending venogram shows (A) the infr
suprarenal inferior vena cava filter, and (C) extensive ca
involving the iliac vein.
Fig 2. Selective pharmacomechanical thrombolysis into
renal vein and (B) right renal vein.C,Complete left renal
cal thrombolysis, with significant residual intrafilter thro
Fig 3. A, Complete thrombus clearance after catheter-d
with patent renal veins. B, Successful filter retrieval withdialysis (creatinine, 1.2 mg/dL). Venous duplex ultrasound imag- lng at 12 months showed no evidence of recurrent thrombus. She
ad improved ambulation with physical therapy, but was still
imited with a cane due to back and knee pain.
ISCUSSION
IVC filter related complications are common. The inci-
ence of postprocedure bleeding, access-site thrombosis, de-
l position of inferior vena cava filter, (B) a migrated
rombus extending to the origins of the renal veins and
renal vein with the DVX catheter is seen in the (A) left
clearance after catheter-directed and pharmacomechani-
.
ed thrombolysis and pharmacomechanical thrombolysis
o residual thrombus on completion venogram.arena
val theach
veinirectivery system complications, and penetration into adjacent
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Late complications and their reported incidences include pul-
monary embolism (0.5% to 4%), nonflow-limiting and occlu-
sive IVC thrombosis (7.7% to28%), post-thrombotic sequelae
(5% to 6%), filter fracture or migration (5% to 20%), and
arteriovenous fistulae.1,5
Filter migration, defined as caudal or cranial movement
1 cm, occurs in 5% to 20% of cases. Migration into the
heart and pulmonary arteries, as well as fragment emboli-
zation into pulmonary arteries or hepatic veins, have been
reported.6 Filter characteristics may affect the incidence of
complications, but no published correlation between filter
design and adverse events exists. The reported incidence of
migration is 12.8% with Greenfield filters (Boston Scientific/
Meditech, Natick, Mass), 1.9% in bird’s nest filters (Cook
Medical, Bloomington, Ind), 2.2% in Simon nitinol filters
(C.R. Bard, Covington, Ga), and 8.3% in Vena Tech filters
(Braun, Bethlehem, Pa).7 Caudal filter migration appears
to be more common with the Recovery G2 filter, with an
incidence of 3.9%,8 but cranial migration has also been
described.9 There are no comparative data to suggest that
the rate of migration of retrievable filters in general is
higher than that of permanent filters.
Reported causes of filter migration are limited, with
operator error often being a precipitating factor. Megacava
(diameter 28 mm) may not provide enough tension for
the filter to stabilize, but did not seem to be a factor in this
patient. We hypothesized that the inciting factor might
have been a large embolus that dislodged the filter and
caused migration. It is difficult, however, to ascertain
whether migration occurred first or was precipitated by a
large embolus. Caval thrombosis can result from initial
filter migration, but the pathogenesis more often relates to
trapped clot in the filter itself initiating extension.10
Caval and renal vein thrombosis have variable presen-
tations, including flank and abdominal pain, oliguria, he-
maturia, azotemia, lower extremity swelling, and post-
thrombotic sequelae.11 Although CDT is widely used for
the treatment of isolated iliocaval thrombosis,1 PMT is
particularly attractive in the setting of end-organ compro-
mise. It allows prompt thrombus debulking and minimiza-
tion of organ injury by restoration of venous outflow.
Recent studies with PMT compared with CDT
alone12-14 demonstrate high success rates in reducing
thrombus burden, including caval and filter thrombosis.15
PMT may also decrease the risk of hemorrhagic complica-
tions with shorter infusion intervals and lower doses of throm-
bolytic agents, making it a more attractive modality in high-
risk postoperative patients. Potential disadvantages include
worsening renal dysfunction caused bymyoglobinuria exacer-
bating preexisting acute renal failure. Our patient was already
receiving hemodialysis, and a delayed bleeding complication
that developed several days after thrombolysis was attributed
to the supratherapeutic anticoagulation.
Filter-related caval thrombosis is likely to recur without
filter removal. When the cause of the occlusion is massive
embolization into the filter, adequate anticoagulation di-
minishes the rate of subsequent thromboembolism.16 Re- Soval of migrated and tilted filters can be challenging and
ay require a dual femoral and jugular approach. Surgical
lter removal and IVC stenting are alternatives that would
ave been considered if percutaneous removal had failed.
ONCLUSIONS
Migration of IVC filters can lead to catastrophic com-
lications, including extension of caval thrombus into the
enal veins with resultant acute renal failure. A high level of
uspicion of filter migration and renal thrombosis is re-
uired when renal dysfunction and acute lower extremity
welling develops. This report highlights the evolving use
f PMT in treating caval and renal vein thrombosis as an
ffective alternative to CDT.
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